IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW

Q3 Pharmacology, Toxicology and Pharmaceutics
A. Zainal, M. Merkhan
{"title":"IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW","authors":"A. Zainal, M. Merkhan","doi":"10.31482/mmsl.2022.004","DOIUrl":null,"url":null,"abstract":"Based on many reports, an unmistakable link probably exists between diabetes mellitus and COVID-19. A major predisposing factor determining severity and mortality of COVID-19 is diabetes mellitus, diabetic patients were shown to be at higher risk for developing severe COVID-19 disease than non-diabetics;many recent studies reported a striking prevalence of DM in those diagnosed with COVID-19. Accordingly, antidiabetic drugs can possibly impact the clinical course and / or the outcome of this infection, either by alleviating diabetes-associated symptoms, minimizing its complications, or by mitigating or aggravating COVID-19 disease by effects independent from their direct antidiabetic effects. Several antidiabetic drug classes were shown to have varying effects, like blocking viral entry to cells, as well as having immunomodulatory, anti-inflammatory, antifibrotic, or cardioprotective effects;such effects could prove beneficial for COVID-19 patients. On the other hand, some antidiabetic agents may have adverse effects that aggravate patients’ condition like hypoglycemia, fluid retention, increased weight or lactic acidosis, which require special consideration in patient management. Some of the drugs were found in observational studies to either reduce mortality from COVID-19 or pose no harm, but more solid evidence from clinical trials is still lacking. © 2022, University of Defence, Faculty of Military Health Sciences. All rights reserved.","PeriodicalId":38749,"journal":{"name":"Vojenske Zdravotnicke Listy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vojenske Zdravotnicke Listy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31482/mmsl.2022.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 4

Abstract

Based on many reports, an unmistakable link probably exists between diabetes mellitus and COVID-19. A major predisposing factor determining severity and mortality of COVID-19 is diabetes mellitus, diabetic patients were shown to be at higher risk for developing severe COVID-19 disease than non-diabetics;many recent studies reported a striking prevalence of DM in those diagnosed with COVID-19. Accordingly, antidiabetic drugs can possibly impact the clinical course and / or the outcome of this infection, either by alleviating diabetes-associated symptoms, minimizing its complications, or by mitigating or aggravating COVID-19 disease by effects independent from their direct antidiabetic effects. Several antidiabetic drug classes were shown to have varying effects, like blocking viral entry to cells, as well as having immunomodulatory, anti-inflammatory, antifibrotic, or cardioprotective effects;such effects could prove beneficial for COVID-19 patients. On the other hand, some antidiabetic agents may have adverse effects that aggravate patients’ condition like hypoglycemia, fluid retention, increased weight or lactic acidosis, which require special consideration in patient management. Some of the drugs were found in observational studies to either reduce mortality from COVID-19 or pose no harm, but more solid evidence from clinical trials is still lacking. © 2022, University of Defence, Faculty of Military Health Sciences. All rights reserved.
降糖药物对COVID-19感染风险和转归的影响
根据许多报道,糖尿病和新冠肺炎之间可能存在明确的联系。决定新冠肺炎严重程度和死亡率的一个主要诱因是糖尿病,糖尿病患者患严重新冠肺炎的风险高于非糖尿病患者;最近的许多研究报告称,在被诊断为新冠肺炎的患者中,DM的患病率惊人。因此,抗糖尿病药物可能会通过减轻糖尿病相关症状、尽量减少并发症,或通过独立于其直接抗糖尿病作用的作用减轻或加重新冠肺炎疾病,从而影响这种感染的临床过程和/或结果。几种抗糖尿病药物被证明具有不同的作用,如阻断病毒进入细胞,以及具有免疫调节、抗炎、抗纤维或心脏保护作用;这种效果可能对新冠肺炎患者有益。另一方面,一些抗糖尿病药物可能会产生副作用,加重患者的病情,如低血糖、液体潴留、体重增加或乳酸酸中毒,这需要在患者管理中特别考虑。一些药物是在观察性研究中发现的,可以降低新冠肺炎的死亡率或不会造成伤害,但临床试验仍缺乏更确凿的证据。©2022,国防大学军事卫生科学学院。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vojenske Zdravotnicke Listy
Vojenske Zdravotnicke Listy Health Professions-Emergency Medical Services
CiteScore
1.00
自引率
0.00%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信